Kazdoba, Tatiana M.
Hagerman, Randi J.
Zolkowska, Dorota
Rogawski, Michael A.
Crawley, Jacqueline N.
Funding for this research was provided by:
National Institute of Mental Health (Grant 5T32MH073124-10)
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT (U54 HD079125)
Article History
Received: 13 June 2015
Accepted: 6 October 2015
First Online: 3 November 2015
Compliance with ethical standards
:
: All procedures were conducted in compliance with the NIH Guidelines for the Care and Use of Laboratory Animals and approved by the UC Davis Institutional Animal Care and Use Committee.
: Dr. Hagerman has received funding from the Department of Defense and from Marinus Pharmaceuticals to study ganaxolone in a controlled trial in fragile X syndrome, both with and without autism. Dr. Rogawski is a consultant to Sage Therapeutics. Drs. Kazdoba, Zolkowska, and Crawley declare that they have no competing interests.